Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase NA 6Phase 1/2 5Phase EARLY_PHASE1 2Phase 3 2Phase 1 2

Status

Completed 15Recruiting 5Withdrawn 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Carcinoma, Non-Small-Cell Lung 155Neoplasms 115Colorectal Neoplasms 97Breast Neoplasms 92Pancreatic Neoplasms 80Neoplasm Metastasis 80Leukemia, Myeloid, Acute 79Recurrence 76Melanoma 74Prostatic Neoplasms 73Ovarian Neoplasms 73Multiple Myeloma 66Stomach Neoplasms 59Squamous Cell Carcinoma of Head and Neck 55Lung Neoplasms 55Triple Negative Breast Neoplasms 50Glioblastoma 48Lymphoma 47Endometrial Neoplasms 43Carcinoma, Hepatocellular 42Advanced Solid Tumor 42Lymphoma, Non-Hodgkin 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Advanced Solid Tumors 37Small Cell Lung Carcinoma 35Uterine Cervical Neoplasms 34Carcinoma, Renal Cell 34Lymphoma, Large B-Cell, Diffuse 32Lymphoma, B-Cell 32Sarcoma 29

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1belantamab mafodotin 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Immunoglobulin Light-chain Amyloidosis × Clear all
NCT05145816 2026-05-07

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

University of Texas Southwestern Medical Center

Phase 1/2 Recruiting
37 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07081646 2026-03-24

ALACRITY

Alexion Pharmaceuticals, Inc.

Phase 1/2 Recruiting
91 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT06569147 2026-03-06

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Brigham and Women's Hospital

Phase 1/2 Recruiting
49 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06097832 2025-07-10

NEXICART-2

Nexcella Inc.

Phase 1/2 Recruiting
40 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡